Status:
COMPLETED
Dose-response Study of Exendin-9,39 on Glucose Metabolism
Lead Sponsor:
Adrian Vella
Conditions:
Pancreatic Effects of 9,39-Exendin and 9,36-GLP-1
Eligibility:
All Genders
20-45 years
Phase:
PHASE1
Brief Summary
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an eff...
Eligibility Criteria
Inclusion
- Healthy Not on any medication other than thyroid hormone replacement or OCP No history of diabetes No prior upper GI surgery
Exclusion
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT01218633
Start Date
May 1 2011
End Date
December 1 2012
Last Update
January 23 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905